NEJM Acceptance Rate

NEJM's editorial process has three stages, and NEJM publishes figures for only some of them:

Stage 1: Desk review (editors only)

• Declined at this stage: about 10% without further editorial consideration (NEJM), with more declined by an associate editor before peer review; NEJM publishes no overall desk-rejection rate

• Timeline: initial in-house review is typically completed in less than one week

• Decision basis: scope, clinical significance, study design at a high level

Stage 2: Peer review (external reviewers)

• Rejection rate: not published by NEJM

• Timeline: in almost all cases, two peer reviewers evaluate each submission within one to two weeks

• Decision basis: methodological rigor, statistical validity, interpretation accuracy

Stage 3: Revision rounds

• Rejection rate: not published by NEJM; multiple iterations of peer review, statistical review, and revision will most likely occur

• Timeline: not published by NEJM

• Decision basis: adequacy of revisions, response to reviewer concerns

So if you submit to NEJM, the odds are against you from the first read: about 5% of original research submissions are published, and about 10% are declined at the very first editorial stage. NEJM does not publish the odds at later stages, and an invitation to revise is not an acceptance.

NEJM says it receives more than 16,000 research and other submissions each year, including over 5,000 original research submissions, and that about 5% of original research submissions achieve publication. NEJM does not publish an acceptance rate for all content types combined.

For context: among the original articles NEJM publishes each year, roughly half are randomized trials. Most of those trials enrolled thousands of patients across dozens of centers with years of follow-up. That's the competition.

The desk screen is the most actionable stage for authors. It means the bottleneck is not only peer review. It is whether the editors decide the paper has enough scope and clinical significance to be worth sending out.

Papers that clear the desk at NEJM tend to share specific characteristics:

• Definitive randomized trials with hard endpoints (mortality, major cardiovascular events, disease-free survival)

• Practice-changing magnitude, not just statistically significant, but large enough and consistent enough to actually shift treatment guidelines

• Broad patient population, findings that apply across the full range of patients a general internist sees, not a narrow subspecialty subgroup

• Clean design, primary endpoint prespecified, powered appropriately, minimal protocol deviations

Papers that get desk-rejected despite strong science:

• Trials with surrogate endpoints instead of hard clinical outcomes

• Post-hoc analyses of trials designed to answer a different primary question

• Studies in populations too narrow for NEJM's general internal medicine readership

• Findings that are significant but not large enough in magnitude to change practice

The 2024 citation value of 84.5 is down from 176.1 in 2021, when NEJM published some of the most-cited clinical trials of the pandemic era including the first mRNA vaccine efficacy data. The post-pandemic equilibrium of 84.5 represents the journal's durable citation base from cardiovascular, oncology, and diabetes trials, not the extraordinary pandemic lift. For authors evaluating career impact, the current 84.5 is the operative number. Papers published in 2021-2022 carry the 176.1 signal for tenure committees that note publication year.

A first-author original article in NEJM is one of the strongest publication signals in clinical medicine. At major academic medical centers, it weighs heavily in hiring, promotion, and grant evaluations. The IF of 78.5 (SJR 20.0, CiteScore 100+) reflects how frequently NEJM papers are cited across the medical literature.

But IF isn't the only consideration. A paper in JAMA or The Lancet as first author at the assistant professor level signals comparable clinical research capabilities. The marginal prestige difference between NEJM and the next tier of clinical journals matters less in practice than whether you have strong first-author publications in any top-tier clinical journal.

The question to ask before submitting to NEJM: would a general internist change how they treat patients based on this finding?

If the answer is clearly yes, a new standard of care, a treatment that should replace current first-line therapy, or a definitive finding about a common intervention, the submission is worth making even knowing the desk rejection rate.

If the answer is "it depends" or "primarily in subspecialty X," the paper probably belongs in a subspecialty journal or in JAMA's broader scope, not in NEJM.

Being honest about this assessment before submitting saves two weeks of waiting for a predictable desk rejection.

If you need a fast decision, use this rule: choose the option that gives the clearest next action within two weeks. In journal strategy, clarity beats optionality. A clear journal fit with a realistic acceptance path is more valuable than chasing a prestige target that predictably desk-rejects your study.

This doesn't mean aiming low. It means matching manuscript type, audience, and significance level honestly, then moving quickly.

Pick one target journal and make a single-page submission brief: study question, primary result, target reader, and one-sentence significance claim. If that brief feels vague, the manuscript framing still needs work before submission.

This short exercise exposes scope mismatches early and reduces avoidable desk rejections.

A NEJM clinical relevance and scope fit check can flag fit issues before you submit, helping you decide whether NEJM or a specialty journal is the stronger first target.

NEJM does not charge authors any submission or publication fees. Authors pay nothing to publish in NEJM, and NEJM does not offer a paid immediate open-access option.

For authors whose funders require public access, NEJM provides a PDF of the Author Accepted Manuscript that can be deposited in a noncommercial repository after publication. Check the NEJM author center FAQ for the current terms.

This means the cost comparison between NEJM and open-access journals like Nature Communications is significant. Authors at institutions without strong open-access agreements can publish in NEJM at no cost, while the same paper in a fully open-access flagship can require a meaningful APC.

The practical implication: for clinical researchers at institutions with limited APC budgets, NEJM is not just the prestige choice, it's also the cost-efficient choice for papers that meet the editorial bar.

Letters to the Editor are a separate, much shorter format. NEJM sets a 175-word limit for a letter about an NEJM article published within the last three weeks and a 400-word limit for a letter that is not about a recent NEJM article.

If you have a targeted observation, reanalysis, or substantive comment on a recently published NEJM article, a letter is a legitimate publication in NEJM without the full manuscript process. Letters are indexed in PubMed and count as NEJM publications on a CV.

The editorial bar for letters is still high. The best strategy is to identify a specific quantitative claim in the original paper, add new information such as your own data, an alternative analysis, or a patient population the original did not cover, and make the point within the word limit.

For manuscripts targeting NEJM, three failure modes show up in most desk-rejection outcomes. Each reflects the journal's standard: practice-changing clinical evidence in large, methodologically rigorous trials with broad applicability to the full range of patients that physicians in general internal medicine encounter.

Trial with surrogate endpoints submitted as practice-changing evidence.

NEJM's editorial standard is that the evidence must be strong enough to change what physicians do. The failure pattern is a well-designed randomized trial reporting statistically significant improvement in a surrogate outcome, such as a biomarker, imaging finding, or intermediate physiological measure, without demonstrating impact on hard clinical endpoints.

A trial showing that treatment X reduces LDL by 25% more than standard care, without data on cardiovascular events or mortality, provides evidence that the drug works on the surrogate without proving that patients live longer or have fewer heart attacks. In our experience, papers relying primarily on surrogate endpoints are unlikely to pass desk review unless hard outcome data is simultaneously not feasible and the clinical question is urgent.

The statistical review NEJM applies once a manuscript is moved to Revision status can also surface these weaknesses.

Narrow subspecialty study with limited generalizability.

The second pattern is a study that is methodologically rigorous and clinically important within one subspecialty without meeting NEJM's standard for broad clinical relevance. NEJM's editorial test is whether a general internist or family physician would change how they treat patients based on the finding.

A trial of a new endoscopic technique for Barrett's esophagus, a study of a dosing protocol for a chemotherapy regimen used only in hematologic oncology, or a head-to-head comparison of two devices used only by interventional radiologists, may each represent important contributions to their respective fields without reaching the breadth of relevance NEJM requires.

Editors identify these papers because the patient population in the abstract is too specific, the clinical question is too narrowly defined, and the readership that would act on the finding is a subspecialty group rather than the general medical community.

Post-hoc analysis or secondary analysis submitted as primary evidence.

The third pattern is a manuscript presenting a secondary analysis of a larger trial, a post-hoc subgroup analysis, or a reanalysis of existing data, framed as a primary clinical finding. NEJM publishes these analyses occasionally when the question is genuinely important and the analysis was pre-specified, but the bar is much higher than for a prospectively designed primary analysis.

The failure pattern we see: a subgroup analysis identified after the primary trial results were known, framed as revealing a differential treatment effect in a patient subgroup, and submitted as if the subgroup finding were the trial's primary contribution. NEJM reviewers distinguish between pre-specified subgroup analyses with adequate power and post-hoc subgroup explorations, and papers where the clinical significance depends on accepting a post-hoc finding as causal evidence face systematic rejection.

A NEJM evidentiary standard and endpoint framing check can assess whether the manuscript's primary endpoint and analysis plan are framed in a way that meets NEJM's evidentiary standard.